טוען...
Total knee replacement with and without emicizumab: a unique comparison of perioperative management
Prophylaxis with emicizumab was used in a patient with severe hemophilia with an inhibitor who underwent knee surgery. Use of emicizumab during surgery led to less recombinant factor VIIa and less bleeding, in addition to cost savings, for this patient.
שמור ב:
| הוצא לאור ב: | Blood Adv |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065482/ https://ncbi.nlm.nih.gov/pubmed/32126140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001060 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|